Explore the options in GVHD prevention and treatment strategies with downloadable slides from this ongoing, live meeting series.
- Increase treatment options for patients with acute and chronic GVHD
- Maximize strategies for prevention and treatment of GVHD
- Improve care giving with tactics for enhanced patient engagement
Apr 30, 2018
Apr 30, 2019
Graft-versus-host disease: Developments in prevention, treatment, and patient engagement
David Miklos, MD, PhD
This program is designed for physicians and registered nurses who comprise the core hematopoietic stem cell transplantation team, as well as community-based oncology physicians and nurses.
After successful completion of this educational activity, participants should be able to:
- Explain the pathophysiology of acute GVHD, as well as the more recent understanding of the biology of chronic GVHD
- Employ new approaches to GVHD prophylaxis when planning care for patients receiving allogeneic hematopoietic stem cell transplant (HSCT) and when providing patient and family education
- Evaluate the potential clinical utility of data on diagnostic and prognostic markers of GVHD
- Utilize treatment and management strategies incorporating new targeted therapies for acute and chronic GVHD based on an understanding of the mechanism of action, benefits, risks, dosing, monitoring, and management of the agents
- Use shared decision making approaches to improve the quality of care for patients receiving allogeneic HSCT who may develop GVHD
This activity is supported by educational grants from Incyte; Pharmacyclics LLC, an AbbVie Company; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Enduring Materials From a Certified Activity
This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.
This activity is organized by prIME Oncology.
Disclosure of Relevant Financial Relationships
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Miklos has disclosed that he has received consulting fees from Adaptive Biotechnologies and Pharmacyclics, and performed contracted research for Pharmacyclics. He has also disclosed that he is a patent holder with PCYC regarding GVHD and ibrutinib. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
- Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
- Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.